BRINGING
YOUR
SCIENCE
TO LIFE
BRINGING
YOUR
SCIENCE
TO LIFE
CARBOGEN AMCIS is a leading service provider CDMO, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development.
Our integrated services for Drug Substances (DS) and Drug Products (DP) provide innovative solutions to support timely and safe drug development.
Besides being a service provider, we also offer High Quality Cholesterol and Vitamin D analog products produced at our facility in The Netherlands. These products are used in a variety of markets around the globe.
Manchester, UK (20 June 2023) – CARBOGEN AMCIS Manchester, a member of the Switzerland-based CARBOGEN AMCIS Group, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, won the Manufacturing and Resource Efficiency Award at the prestigious Chemistry Industry Awards last week.
CARBOGEN AMCIS Manchester won the industry award in recognition of its efficiency improvement program implemented in response to...
BUBENDORF, Switzerland (02 june 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at its headquarters in Bubendorf, Switzerland and a Swissmedic routine inspection at Bubendorf, Aarau and Neuland, Switzerland.
From December 8th - 16th 2022, a seven-day surveillance...
Bubendorf, Switzerland (3 February 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has opened a state-of-the-art facility in Saint-Beauzire, France.
The new site is dedicated to the custom development and production of sterile injectable drug products. Built on newly acquired land located 7km from an existing CARBOGEN AMCIS site in Riom, the new facility increases product...
Bubendorf, Switzerland (Septembre 29, 2022) – Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that its site in Vionnaz, Switzerland has successfully completed a Swissmedic inspection performed by Regional Medicines Inspectorate of Western Switzerland (ISOPTh).
The two-day inspection took place from September 20th to 21th, 2022 and was undertaken by an inspector of Regional Medicines Inspectorate of Western Switzerland...
BUBENDORF, Switzerland (July 21, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today the appointment of François Baduel as Vice President of Business Development, Sales & Marketing.
In his new role, François Baduel will lead the company’s overall sales and marketing operations. He will report directly to Pascal Villemagne, Chief Executive Officer,...
BUBENDORF, Switzerland (March 31, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that Pascal Villemagne has been named Chief Executive Officer, effective first of April
In his new role, Pascal Villemagne will be leading CARBOGEN AMCIS and its nine sites around the world. He will report to Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd., CARBOGEN AMCIS’ parent company. Villemagne, who has served as Vice President of Sales...
Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte...
MEYLAN, France, BUBENDORF, Switzerland, (November 3rd, 2021) - NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and Drug Products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.
CARBOGEN AMCIS just released the fifth batch of AGuIX Drug Product since inception of the company. The release of this 3.7 kg batch...
BUBENDORF, Switzerland (27 October 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at the site in Aarau, Switzerland.
The pre-approval FDA paper inspection for an intermediate product from a customer was conducted from 17 August - 15 September 2021. By receiving the result in October 2021 the inspection was concluded successfully with no findings, confirming that...
BUBENDORF, Switzerland (27 Aug 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co-investment agreement with one of its key European customers.
The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and is following a previous investment of CHF 6 million.
The recent...
BUBENDORF, Switzerland (24 June, 2021) Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced the acquisition of a new property in Bubendorf.
CARBOGEN AMCIS confirms the acquisition of further property in Bubendorf (Basel-Landschaft), where the company's headquarters are located. The property in Hauptstrasse 175 has been acquired from the previous owners Marcel und Theres Rutschmann and...
BUBENDORF, Switzerland (April 29th, 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long standing Japan based customer to build a site extension at the Bubendorf site in Switzerland.
The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will...
3 Place Bellevue, 64200 Biarritz, France
O38
10/10/2023 - 12/10/2023
From to
For more than 30 years, A3P has been uniting an international network of skills and experiences to meet the technological and regulatory requirements of the pharmaceutical, bioproduction and cosmetic industry. Each year, nearly 650 professionals from the pharmaceutical and biotech industries meet in Biarritz to share their experiences and discover the technical and scientific innovations of the moment.
Pacifico Yokohama, Japan
@Swiss Pavilion
11/10/2023 - 13/10/2023
From to
BioJapan is the world's oldest biotechnology exhibition which attracts overseas exhibitors from 26 countries around 15'000 visitors annually.
We look forward to meet you at the Swiss Pavilion.
Orange County Convention Center Orlando
Booth #3330
22/10/2023 - 25/10/2023
From to
AAPS is the convener of the pharmaceutical science community, bringing together thousands of scientists from across the world and the drug development process. For them, PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a small niche meeting because of its unique programming structure. PharmSci 360 is built on six tracks that offer both chemical and biomolecular drug programming in symposia, rapid fire presentations, and posters. Scientists attending the meeting report that they build their schedule to solve their problems, and may attend programming in only one track or all of them!
Fira Barcelona
3G39
24/10/2023 - 26/10/2023
From to
CPhI Worldwide will return to Barcelona from 24 - 26 October 2023. Over the last 30+ years, CPhI has provided a unique platform that unites specialist communities dedicated to improving healthcare. We offer a place where professionals can meet to exchange knowledge and do business without obstacles, helping to propel the pharmaceutical and healthcare industries forward.
Manchester Central
30
28/11/2023 - 29/11/2023
From to
Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. BOS is an event where business gets gone and where you can be confident of high quality interactions with potential business partners. You will receive a warm welcome from the Bio2Business team in the vibrant and buzzing City of Manchester!
BOS Manchester 2023 scope is primarily development stage CMC outsourcing for both Small Molecules and Biologics and also covering Novel Therapeutic Entities.
The BOS Events story began in 2006 with the 1st event hosted in Sheffield, UK. The event format has been refined over the years and now consists of 4 key components; Programme; Partnering; Exhibition and Informal Networking.
Get in contact with us and let's meet in Manchester.
Marseille, France
12/12/2023 - 13/12/2023
From to
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development. Our integrated services for Drug Substances (DS) and Drug Products (DP) provide innovative solutions to support timely and safe drug development.